Baxter Reports Third-Quarter 2024 Results
Baxter (BAX) reported Q3 2024 total sales of $3.85 billion, with continuing operations sales of $2.70 billion increasing 4% on both reported and constant currency basis. The company achieved total U.S. GAAP diluted EPS of $0.27 and adjusted EPS of $0.80, exceeding previous guidance. Hurricane Helene significantly impacted the North Cove facility, though production has restarted on the highest-throughput IV solutions line. The company announced the pending sale of its Kidney Care business to Carlyle for $3.80 billion, expected to close in late 2024 or early 2025. Due to hurricane impact, Baxter adjusted its full-year 2024 outlook, expecting total company sales growth of 1-2% and adjusted EPS of $2.90-$2.94.
Baxter (BAX) ha riportato vendite totali per il terzo trimestre del 2024 pari a 3,85 miliardi di dollari, con vendite delle operazioni continuative di 2,70 miliardi di dollari in aumento del 4% sia in base ai risultati riportati che ai tassi di cambio costanti. L'azienda ha raggiunto un utile per azione (EPS) diluito GAAP degli Stati Uniti di 0,27 dollari e un EPS rettificato di 0,80 dollari, superando le precedenti previsioni. Uragano Helene ha avuto un impatto significativo sull'impianto North Cove, sebbene la produzione sia ripresa sulla linea di soluzioni IV a più alta capacità. L'azienda ha annunciato la vendita imminente della sua attività di cura dei reni a Carlyle per 3,80 miliardi di dollari, prevista per la fine del 2024 o l'inizio del 2025. A causa dell'impatto dell'uragano, Baxter ha rivisto le sue previsioni per l'intero anno 2024, aspettandosi una crescita delle vendite aziendali totali dell'1-2% e un EPS rettificato di 2,90-2,94 dollari.
Baxter (BAX) reportó ventas totales del tercer trimestre de 2024 por 3.85 mil millones de dólares, con ventas de operaciones continuas de 2.70 mil millones de dólares que aumentaron un 4% tanto en términos reportados como en moneda constante. La compañía logró un EPS diluido GAAP de EE. UU. de 0.27 dólares y un EPS ajustado de 0.80 dólares, superando la guía anterior. El huracán Helene impactó significativamente la instalación de North Cove, aunque la producción se reinició en la línea de soluciones IV de mayor capacidad. La compañía anunció la venta pendiente de su negocio de Cuidados Renales a Carlyle por 3.80 mil millones de dólares, que se espera cierre a finales de 2024 o principios de 2025. Debido al impacto del huracán, Baxter ajustó su perspectiva para todo el año 2024, esperando un crecimiento de ventas totales de la empresa del 1-2% y un EPS ajustado de 2.90-2.94 dólares.
백스터(BAX)는 2024년 3분기 총 매출이 38억 5천만 달러에 달하며, 지속적인 운영 매출이 27억 달러로 보고 및 상수 통화 기준 모두 4% 증가했다고 보고했습니다. 이 회사는 미국 GAAP 기준으로 희석 주당 순이익(EPS)이 0.27달러, 조정된 EPS가 0.80달러로 이전 가이던스를 초과했습니다. 허리케인 헬렌은 노스 코브 시설에 상당한 영향을 미쳤지만, 생산은 최대 생산량의 IV 솔루션 라인에서 재개되었습니다. 이 회사는 38억 달러에 신장 관리 사업을 Carlyle에 매각할 예정이며, 2024년 말 또는 2025년 초에 마감될 것으로 예상하고 있습니다. 허리케인의 영향으로 Baxter는 2024 회계 연도 전체 전망을 조정하여 총 매출 성장률을 1-2%와 조정된 EPS를 2.90-2.94달러로 예상했습니다.
Baxter (BAX) a annoncé des ventes totales pour le troisième trimestre 2024 s'élevant à 3,85 milliards de dollars, avec des ventes des opérations continues de 2,70 milliards de dollars, en augmentation de 4 % tant en base reportée qu'en valeur constante. La société a atteint un bénéfice par action dilué conforme aux principes comptables généralement admis (GAAP) de 0,27 dollar et un bénéfice ajusté par action de 0,80 dollar, dépassant les prévisions précédentes. Les ouragans Helene ont eu un impact significatif sur l'installation de North Cove, bien que la production ait redémarré sur la ligne de solutions intraveineuses à plus haut débit. L'entreprise a annoncé la vente imminente de son activité de soins rénaux à Carlyle pour 3,80 milliards de dollars, qui devrait se clôturer fin 2024 ou début 2025. En raison de l'impact de l'ouragan, Baxter a ajusté ses prévisions pour l'ensemble de l'année 2024, s'attendant à une croissance des ventes globales de 1 à 2 % et à un bénéfice ajusté par action de 2,90 à 2,94 dollars.
Baxter (BAX) meldete für das dritte Quartal 2024 einen Umsatz von 3,85 Milliarden Dollar, wobei der Umsatz aus fortgeführten Betrieben bei 2,70 Milliarden Dollar lag und sowohl in Berichts- als auch in konstanten Währungsbeträgen um 4 % gestiegen ist. Das Unternehmen erzielte einen verwässerten GAAP-Gewinn pro Aktie (EPS) von 0,27 Dollar und einen bereinigten EPS von 0,80 Dollar, was die vorherige Prognose übertraf. Hurrikan Helene hatte erhebliche Auswirkungen auf die North Cove-Anlage, obwohl die Produktion auf der Linie für IV-Lösungen mit der höchsten Durchsatzrate wieder aufgenommen wurde. Das Unternehmen gab den bevorstehenden Verkauf seiner Nierensondergeschäfts an Carlyle für 3,80 Milliarden Dollar bekannt, der voraussichtlich Ende 2024 oder Anfang 2025 abgeschlossen wird. Aufgrund der Auswirkungen des Hurrikans hat Baxter seine Gesamtprognose für 2024 angepasst und rechnet mit einem Umsatzwachstum des Gesamtkonzerns von 1-2 % und einem bereinigten EPS von 2,90-2,94 Dollar.
- Q3 sales from continuing operations grew 4% to $2.70 billion
- Adjusted EPS of $0.80 exceeded company guidance
- Kidney Care sale to generate approximately $3.50 billion in cash proceeds
- Successfully restarted highest-throughput IV solutions manufacturing line at North Cove
- Hurricane Helene expected to impact Q4 sales by approximately $200 million
- Q4 adjusted EPS expected to be negatively impacted by $0.15-$0.20 per share
- Downward revision of full-year 2024 financial outlook
- Stranded costs from Kidney Care sale will impact margins through 2027
Insights
Baxter's Q3 results reveal a mixed performance with notable challenges ahead. Sales from continuing operations reached
The significant impact of Hurricane Helene on the North Cove facility is expected to reduce Q4 sales by approximately
The company's revised full-year 2024 outlook now projects total company sales growth of
The North Cove facility recovery demonstrates both operational challenges and resilience. The restart of the highest-throughput IV solutions manufacturing line, representing
Post-Kidney Care divestiture, Baxter faces operational adjustments including managing stranded costs and transition service agreements. The company's target of
-
Baxter third-quarter 2024 sales totaled
1$3.85 billion -
Third-quarter total Baxter
U.S. GAAP2 diluted earnings per share (EPS) were 1; adjusted total Baxter diluted EPS were$0.27 1, exceeding the company’s previously issued guidance$0.80 -
Third-quarter sales from continuing operations of
increased$2.70 billion 4% on both a reported and constant currency basis3, reflecting growth across all segments4 -
Third-quarter
U.S. GAAP diluted EPS from continuing operations were ; adjusted continuing operations EPS were$0.12 $0.49 -
Baxter continues to make significant progress restoring production at its North Cove facility following the unprecedented impact of Hurricane Helene in western
North Carolina ; production has now restarted on the facility’s highest-throughput IV solutions manufacturing line
“Baxter delivered positive performance in the third quarter of 2024, as the company continues to execute against its strategic transformation,” said José (Joe) E. Almeida, chair, president and chief executive officer. “The pending sale of our Kidney Care business represents another defining milestone in our ongoing transformation journey. We are also making substantial progress advancing hurricane recovery efforts at our North Cove,
Third-Quarter Financial Results
Note that Baxter’s third-quarter and updated full-year 2024 guidance was issued on Aug. 6, 2024, prior to the announcement of the pending sale of the Kidney Care segment to
Total Baxter worldwide sales for Q3 2024 were
On a continuing operations basis, Baxter’s sales of
Kidney Care sales, which are now reported as discontinued operations, increased mid-single digits over the prior year period and were driven by positive demand and pricing for acute therapies and peritoneal dialysis products.
Please see the attached schedules accompanying this press release for additional details on sales performance in the quarter, including breakouts by Baxter’s segments.
For the third quarter, total net income attributable to Baxter on a
Hurricane Helene Recovery at North Cove Facility
On Sept. 27, 2024, western
As announced last week, Baxter has now restarted North Cove’s highest-throughput IV solutions manufacturing line. At its peak operation (prior to Hurricane Helene), this line represented approximately
“I want to recognize the tireless efforts of our North Cove team as well as the countless other Baxter colleagues globally who have committed themselves to site restoration and helping address supply continuity amid this crisis,” said Almeida. “I also offer Baxter’s gratitude to ASPR, FDA, the
Baxter does not yet have a timeline for when North Cove production will be fully restored to pre-hurricane levels. Assessment, equipment repair, and phased testing continue at a rapid pace across all other North Cove production lines, and Baxter will continue to work in close coordination with FDA to resume operations in phases.
Additional information on the restoration effort, including plant recovery, supply continuity, and how Baxter is making a difference for its employees and the community, can be found on the Hurricane Helene Updates page on Baxter.com. The company intends to provide further updates regarding its progress on this page.
Kidney Care Separation Update
On Aug. 13, 2024, Baxter and certain affiliates of global investment firm
Baxter continues to expect the sale to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions.
In light of the reporting change moving Kidney Care business results to discontinued operations, corporate costs that had previously been allocated to the Kidney Care segment, which will not convey with the Kidney Care business in the sale, are now reported in unallocated corporate costs. These stranded costs (or dis-synergies) are expected to be mitigated in 2025 through income to be received from Vantive under transition service agreements (TSAs) as well as cost-containment initiatives the company is in the process of undertaking. Baxter currently expects to fully offset the impact of these stranded costs and loss of TSA income in 2027.
Financial Outlook
Given the unprecedented impact of Hurricane Helene on the company’s North Cove operations and related production, Baxter is adjusting its full-year 2024 financial outlook to reflect the estimated impact of the hurricane on its fourth-quarter results. As a result of the hurricane, Baxter expects total company fourth-quarter sales to be negatively impacted by approximately
Guidance provided below includes the impact of Kidney Care discontinued operations and excludes the impact of BPS discontinued operations. In addition, the company’s updated guidance reflects the anticipated fourth-quarter negative impact of Hurricane Helene.
For full-year 2024: Baxter now expects total company sales growth of
For fourth-quarter 2024: The company expects sales to decline low single digits on both a reported basis and constant currency basis. The company expects total adjusted earnings, before special items, of
Following Kidney Care divestiture: Baxter reaffirms the preliminary financial expectations set when it announced its agreement to sell Kidney Care to
A webcast of Baxter’s third-quarter 2024 conference call for investors can be accessed live from a link in the Investor Relations section of the company’s website at www.baxter.com beginning at 7:30 a.m. CST on Nov. 8, 2024. Please see www.baxter.com for more information regarding this and future investor events and webcasts.
About Baxter
Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, nutrition, kidney care, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.
Non-GAAP Financial Measures
Non-GAAP financial measures may enhance an understanding of the company’s operations and may facilitate an analysis of those operations, particularly in evaluating performance from one period to another. Management believes that non-GAAP financial measures, when used in conjunction with the results presented in accordance with
Net sales growth on a constant currency basis is a non-GAAP financial measure that provides information on the percentage change in net sales growth as if foreign currency exchange rates had remained constant between the prior and current periods. Operational sales growth excludes the impact of the Kidney Care MSA (to be entered into at closing) and is calculated on a constant currency basis.
Other non-GAAP financial measures included in this release and the accompanying tables (including within the tables that provide the company’s detailed reconciliations to the corresponding
This release and the accompanying tables also include free cash flow, a non-GAAP financial measure that Baxter defines as operating cash flow less capital expenditures. Free cash flow is used by management and the company’s Board of Directors to evaluate the cash generated from Baxter’s operating activities each period after deducting its capital spending.
This release also includes forecasts of certain of the aforementioned non-GAAP measures on a forward-looking basis as part of the company’s financial outlook for the remainder of 2024. Baxter calculates forward-looking non-GAAP financial measures based on forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking annual operational sales growth represents the company’s targeted future sales growth excluding sales to Vantive under the related MSA and assuming foreign currency exchange rates remain constant in future periods. Additionally, forward-looking full year 2025 adjusted operating margin guidance and forward-looking adjusted diluted EPS guidance excludes potential charges or gains that would be reflected as non-GAAP adjustments to earnings. Baxter provides forward-looking annual operational sales growth guidance, forward-looking full year 2025 adjusted operating margin guidance, and forward-looking adjusted diluted EPS guidance because it believes that these measures provide useful information for the reasons noted above. Baxter has not provided reconciliations of forward-looking annual operational sales growth guidance to forward-looking GAAP reported sales growth guidance, forward-looking full year 2025 adjusted operating margin guidance to forward-looking GAAP operating margin guidance, and forward-looking adjusted EPS guidance to forward-looking GAAP EPS guidance for the fourth quarter and full year 2024 because the company is unable to predict with reasonable certainty the impact of legal proceedings, future business optimization actions, separation-related costs, integration-related costs, asset impairments, unusual gains and losses, and changes in foreign currency exchange rates, and the related amounts are unavailable without unreasonable efforts (as specified in the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K). In addition, Baxter believes that such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.
Forward-Looking Statements
This release includes forward-looking statements concerning the company’s financial results (including the outlook for fourth-quarter and full-year 2024, and full-year 2025) and business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company’s ability to execute and complete strategic initiatives, asset dispositions and other transactions and development activities, including the pending sale of the company’s Kidney Care business, the company’s plans to simplify its manufacturing footprint, the timing for such transactions and risks associated with a consolidated manufacturing footprint, the ability to satisfy any applicable conditions and the expected proceeds, consideration and realization of anticipated benefits; failure to accurately forecast or achieve the company’s short- and long-term financial performance and goals (including with respect to the company’s strategic initiatives and other actions, including Hurricane Helene recovery efforts and cost-containment initiatives) and related impacts on its liquidity; the company’s ability to execute on its capital allocation plans, including the company’s debt repayment plans, the timing and amount of any dividends, share repurchases and divestiture proceeds; the company’s ability to successfully integrate acquisitions; the impact of global economic conditions (including, among other things, inflation levels, interest rates, financial market volatility, banking crises, the potential for a recession, the war in
Baxter, Dose IQ and Novum IQ are trademarks of Baxter International Inc.
Any other trademarks or product brands appearing herein are the property of their respective owners.
____________________________ |
1 Includes discontinued operations from Kidney Care business. |
2 Generally Accepted Accounting Principles |
3 Sales growth at constant currency rates and adjusted diluted EPS, as well as forecasts of those items on a forward-looking basis, are non-GAAP financial measures. See the “Non-GAAP Financial Measures” section below for information about the non-GAAP financial measures included in this release and see the accompanying tables to this press release for reconciliations of those non-GAAP measures to the corresponding |
4 Continuing operations include Baxter’s Medical Products & Therapies, Healthcare Systems & Technologies and Pharmaceuticals segments. |
5 Operational sales growth excludes the impact of the Kidney Care manufacturing supply agreement (to be entered into at closing) and is calculated on a constant currency basis. |
BAXTER INTERNATIONAL INC. Consolidated Statements of Income (Loss) (unaudited) (in millions, except per share and percentage data)
|
|||||||||
|
Three Months Ended
|
|
|
||||||
|
|
2024 |
|
|
|
2023 |
|
|
Change |
NET SALES |
$ |
2,699 |
|
|
$ |
2,599 |
|
|
|
COST OF SALES |
|
1,666 |
|
|
|
1,543 |
|
|
|
GROSS MARGIN |
|
1,033 |
|
|
|
1,056 |
|
|
(2)% |
% of Net Sales |
|
38.3 |
% |
|
|
40.6 |
% |
|
(2.3) pts |
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES |
|
754 |
|
|
|
744 |
|
|
|
% of Net Sales |
|
27.9 |
% |
|
|
28.6 |
% |
|
(0.7) pts |
RESEARCH AND DEVELOPMENT EXPENSES |
|
129 |
|
|
|
133 |
|
|
(3)% |
% of Net Sales |
|
4.8 |
% |
|
|
5.1 |
% |
|
(0.3) pts |
OTHER OPERATING INCOME, NET |
|
(5 |
) |
|
|
— |
|
|
NM |
OPERATING INCOME |
|
155 |
|
|
|
179 |
|
|
(13)% |
% of Net Sales |
|
5.7 |
% |
|
|
6.9 |
% |
|
(1.2) pts |
INTEREST EXPENSE, NET |
|
87 |
|
|
|
127 |
|
|
(31)% |
OTHER (INCOME) EXPENSE, NET |
|
(1 |
) |
|
|
(12 |
) |
|
(92)% |
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES |
|
69 |
|
|
|
64 |
|
|
|
INCOME TAX EXPENSE |
|
8 |
|
|
|
27 |
|
|
(70)% |
% of Income from Continuing Operations Before Income Taxes |
|
11.6 |
% |
|
|
42.2 |
% |
|
(30.6) pts |
INCOME FROM CONTINUING OPERATIONS |
|
61 |
|
|
|
37 |
|
|
|
INCOME FROM DISCONTINUED OPERATIONS, NET OF TAX |
|
83 |
|
|
|
2,474 |
|
|
(97)% |
NET INCOME |
|
144 |
|
|
|
2,511 |
|
|
(94)% |
NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS INCLUDED IN CONTINUING OPERATIONS |
|
— |
|
|
|
— |
|
|
NM |
NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS INCLUDED IN DISCONTINUED OPERATIONS |
|
4 |
|
|
|
3 |
|
|
|
NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS |
|
4 |
|
|
|
3 |
|
|
|
NET INCOME ATTRIBUTABLE TO BAXTER STOCKHOLDERS |
$ |
140 |
|
|
$ |
2,508 |
|
|
(94)% |
INCOME FROM CONTINUING OPERATIONS PER COMMON SHARE |
|
|
|
|
|
||||
Basic |
$ |
0.12 |
|
|
$ |
0.07 |
|
|
|
Diluted |
$ |
0.12 |
|
|
$ |
0.07 |
|
|
|
INCOME FROM DISCONTINUED OPERATIONS PER COMMON SHARE |
|
|
|
|
|
||||
Basic |
$ |
0.15 |
|
|
$ |
4.88 |
|
|
(97)% |
Diluted |
$ |
0.15 |
|
|
$ |
4.86 |
|
|
(97)% |
INCOME PER COMMON SHARE |
|
|
|
|
|
||||
Basic |
$ |
0.27 |
|
|
$ |
4.95 |
|
|
(95)% |
Diluted |
$ |
0.27 |
|
|
$ |
4.93 |
|
|
(95)% |
WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING |
|
|
|
|
|
||||
Basic |
|
510 |
|
|
|
507 |
|
|
|
Diluted |
|
512 |
|
|
|
509 |
|
|
|
ADJUSTED OPERATING INCOME (excluding special items)¹ |
$ |
391 |
|
|
$ |
401 |
|
|
(2)% |
ADJUSTED INCOME FROM CONTINUING OPERATIONS (excluding special items)¹ |
$ |
252 |
|
|
$ |
221 |
|
|
|
ADJUSTED INCOME FROM DISCONTINUED OPERATIONS (excluding special items)1 |
$ |
163 |
|
|
$ |
197 |
|
|
(17)% |
ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER STOCKHOLDERS (excluding special items)¹ |
$ |
411 |
|
|
$ |
415 |
|
|
(1)% |
ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS (excluding special items)¹ |
$ |
0.49 |
|
|
$ |
0.43 |
|
|
|
ADJUSTED DILUTED EPS FROM DISCONTINUED OPERATIONS (excluding special items)¹ |
$ |
0.31 |
|
|
$ |
0.39 |
|
|
(21)% |
ADJUSTED DILUTED EPS (excluding special items)¹ |
$ |
0.80 |
|
|
$ |
0.82 |
|
|
(2)% |
1 |
Refer to page 11 for a description of the adjustments and a reconciliation to |
NM - Not Meaningful |
BAXTER INTERNATIONAL INC.
Description of Adjustments and Reconciliation of (unaudited, in millions)
The company’s
|
||||||||||||||||||||||||||||||||||||
|
Gross Margin |
Selling, General and Administrative Expenses |
Operating Income |
Income From Continuing Operations Before Income Taxes |
Income Tax Expense |
Income From Continuing Operations |
Income From Discontinued Operations, Net of Tax |
Net Income |
Net Income Attributable to Baxter Stockholders |
Diluted Earnings Per Share from Continuing Operations |
Diluted Earnings Per Share from Discontinued Operations |
Diluted Earnings Per Share |
||||||||||||||||||||||||
Reported |
$ |
1,033 |
|
$ |
754 |
|
$ |
155 |
|
$ |
69 |
|
$ |
8 |
|
$ |
61 |
|
$ |
83 |
|
$ |
144 |
|
$ |
140 |
|
$ |
0.12 |
$ |
0.15 |
$ |
0.27 |
|||
Reported percent of net sales (or effective tax rate for income tax expense) |
|
38.3 |
% |
|
27.9 |
% |
|
5.7 |
% |
|
2.6 |
% |
|
11.6 |
% |
|
2.3 |
% |
|
3.1 |
% |
|
5.3 |
% |
|
5.2 |
% |
|
|
|
||||||
Intangible asset amortization |
|
108 |
|
|
(51 |
) |
|
159 |
|
|
159 |
|
|
38 |
|
|
121 |
|
|
3 |
|
|
124 |
|
|
124 |
|
|
0.24 |
|
|
0.00 |
|
|
0.24 |
|
Business optimization items1 |
|
2 |
|
|
(16 |
) |
|
18 |
|
|
18 |
|
|
5 |
|
|
13 |
|
|
18 |
|
|
31 |
|
|
31 |
|
|
0.03 |
|
|
0.03 |
|
|
0.06 |
|
Acquisition and integration items2 |
|
— |
|
|
(5 |
) |
|
5 |
|
|
5 |
|
|
1 |
|
|
4 |
|
|
— |
|
|
4 |
|
|
4 |
|
|
0.01 |
|
|
0.00 |
|
|
0.01 |
|
European medical devices regulation3 |
|
9 |
|
|
— |
|
|
9 |
|
|
9 |
|
|
2 |
|
|
7 |
|
|
1 |
|
|
8 |
|
|
8 |
|
|
0.01 |
|
|
0.01 |
|
|
0.02 |
|
Product related reserves4 |
|
3 |
|
|
— |
|
|
3 |
|
|
3 |
|
|
— |
|
|
3 |
|
|
— |
|
|
3 |
|
|
3 |
|
|
0.01 |
|
|
0.00 |
|
|
0.01 |
|
Hurricane Helene costs5 |
|
25 |
|
|
— |
|
|
25 |
|
|
25 |
|
|
6 |
|
|
19 |
|
|
— |
|
|
19 |
|
|
19 |
|
|
0.04 |
|
|
0.00 |
|
|
0.04 |
|
Legal matters6 |
|
— |
|
|
(17 |
) |
|
17 |
|
|
17 |
|
|
4 |
|
|
13 |
|
|
— |
|
|
13 |
|
|
13 |
|
|
0.03 |
|
|
0.00 |
|
|
0.03 |
|
Separation-related costs7 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
46 |
|
|
46 |
|
|
46 |
|
|
0.00 |
|
|
0.09 |
|
|
0.09 |
|
Tax matters10 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(11 |
) |
|
11 |
|
|
12 |
|
|
23 |
|
|
23 |
|
|
0.02 |
|
|
0.02 |
|
|
0.04 |
|
Adjusted |
$ |
1,180 |
|
$ |
665 |
|
$ |
391 |
|
$ |
305 |
|
$ |
53 |
|
$ |
252 |
|
$ |
163 |
|
$ |
415 |
|
$ |
411 |
|
$ |
0.49 |
|
$ |
0.31 |
|
$ |
0.80 |
|
Adjusted percent of net sales (or effective tax rate for income tax expense) |
|
43.7 |
% |
|
24.6 |
% |
|
14.5 |
% |
|
11.3 |
% |
|
17.4 |
% |
|
9.3 |
% |
|
6.0 |
% |
|
15.4 |
% |
|
15.2 |
% |
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
|
|
|
|
Reported |
Adjusted |
|
|
|
|
|
|
|
||||||||||||||||||||||||
Income from discontinued operations, net of tax |
|
$ |
83 |
|
$ |
163 |
|
|
|
|
|
|
|
|
||||||||||||||||||||||
Less: Net income attributable to noncontrolling interests included in discontinued operations |
|
4 |
|
|
4 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Income from discontinued operations, net of tax attributable to Baxter stockholders |
$ |
79 |
|
$ |
159 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
|
|
|
|
Reported |
Adjusted |
|
|
|
|
|
|
|
||||||||||||||||||||||||
Net income (loss) |
|
$ |
144 |
|
$ |
415 |
|
|
|
|
|
|
|
|
||||||||||||||||||||||
Less: Net income attributable to noncontrolling interests |
|
|
4 |
|
|
4 |
|
|
|
|
|
|
|
|
||||||||||||||||||||||
Net income (loss) attributable to Baxter stockholders |
$ |
140 |
|
$ |
411 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
The company’s
|
|||||||||||||||||||||||||||||||||||||||
|
Gross Margin |
Selling, General and Administrative Expenses |
Research and Development Expenses |
Operating Income |
Income From Continuing Operations Before Income Taxes |
Income Tax Expense |
Income From Continuing Operations |
Income From Discontinued Operations |
Net Income |
Net Income Attributable to Baxter Stockholders |
Diluted Earnings Per Share from Continuing Operations |
Diluted Earnings Per Share from Discontinued Operations |
Diluted Earnings Per Share |
||||||||||||||||||||||||||
Reported |
$ |
1,056 |
|
$ |
744 |
|
$ |
133 |
|
$ |
179 |
|
$ |
64 |
|
$ |
27 |
|
$ |
37 |
|
$ |
2,474 |
|
$ |
2,511 |
|
$ |
2,508 |
|
$ |
0.07 |
$ |
4.86 |
$ |
4.93 |
|||
Reported percent of net sales (or effective tax rate for income tax expense) |
|
40.6 |
% |
|
28.6 |
% |
|
5.1 |
% |
|
6.9 |
% |
|
2.5 |
% |
|
42.2 |
% |
|
1.4 |
% |
|
95.2 |
% |
|
96.6 |
% |
|
96.5 |
% |
|
|
|
||||||
Intangible asset amortization |
|
96 |
|
|
(51 |
) |
|
— |
|
|
147 |
|
|
147 |
|
|
34 |
|
|
113 |
|
|
14 |
|
|
127 |
|
|
127 |
|
|
0.22 |
|
|
0.03 |
|
|
0.25 |
|
Business optimization items1 |
|
— |
|
|
(44 |
) |
|
(4 |
) |
|
48 |
|
|
48 |
|
|
12 |
|
|
36 |
|
|
27 |
|
|
63 |
|
|
63 |
|
|
0.07 |
|
|
0.05 |
|
|
0.12 |
|
Acquisition and integration items2 |
|
1 |
|
|
(1 |
) |
|
— |
|
|
2 |
|
|
2 |
|
|
1 |
|
|
1 |
|
|
— |
|
|
1 |
|
|
1 |
|
|
0.00 |
|
|
0.00 |
|
|
0.00 |
|
European medical devices regulation3 |
|
12 |
|
|
— |
|
|
— |
|
|
12 |
|
|
12 |
|
|
4 |
|
|
8 |
|
|
2 |
|
|
10 |
|
|
10 |
|
|
0.02 |
|
|
0.00 |
|
|
0.02 |
|
Legal matters6 |
|
— |
|
|
(13 |
) |
|
— |
|
|
13 |
|
|
13 |
|
|
3 |
|
|
10 |
|
|
— |
|
|
10 |
|
|
10 |
|
|
0.02 |
|
|
0.00 |
|
|
0.02 |
|
Separation-related costs7 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
81 |
|
|
81 |
|
|
81 |
|
|
0.00 |
|
|
0.16 |
|
|
0.16 |
|
Long-lived asset impairments8 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
205 |
|
|
205 |
|
|
205 |
|
|
0.00 |
|
|
0.40 |
|
|
0.40 |
|
Gain on BPS Sale9 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(2,603 |
) |
|
(2,603 |
) |
|
(2,603 |
) |
|
0.00 |
|
|
(5.13 |
) |
|
(5.13 |
) |
Tax matters10 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(16 |
) |
|
16 |
|
|
3 |
|
|
13 |
|
|
13 |
|
|
0.03 |
|
|
0.00 |
|
|
0.03 |
|
Adjusted |
$ |
1,165 |
|
$ |
635 |
|
$ |
129 |
|
$ |
401 |
|
$ |
286 |
|
$ |
65 |
|
$ |
221 |
|
$ |
197 |
|
$ |
418 |
|
$ |
415 |
|
$ |
0.43 |
|
$ |
0.39 |
|
$ |
0.82 |
|
Adjusted percent of net sales (or effective tax rate for income tax expense) |
|
44.8 |
% |
|
24.4 |
% |
|
5.0 |
% |
|
15.4 |
% |
|
11.0 |
% |
|
22.7 |
% |
|
8.5 |
% |
|
7.6 |
% |
|
16.1 |
% |
|
16.0 |
% |
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||
|
|
|
|
|
Reported |
Adjusted |
|
|
|
|
|
|
|
||||||||||||||||||||||||||
Income from discontinued operations, net of tax |
|
$ |
2,474 |
|
$ |
197 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Less: Net income attributable to noncontrolling interests included in discontinued operations |
|
3 |
|
|
3 |
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||
Income from discontinued operations, net of tax attributable to Baxter stockholders |
$ |
2,471 |
|
$ |
194 |
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||
|
|
|
|
|
Reported |
Adjusted |
|
|
|
|
|
|
|
||||||||||||||||||||||||||
Net income (loss) |
|
$ |
2,511 |
|
$ |
418 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Less: Net income attributable to noncontrolling interests |
|
|
3 |
|
|
3 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Net income (loss) attributable to Baxter stockholders |
$ |
2,508 |
|
$ |
415 |
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
The company’s results in 2024 and 2023 included costs related to programs to optimize its organization and cost structure. The company's results of continuing operations in 2024 and 2023 included costs primarily related to its implementation of a new operating model intended to simplify and streamline its operations and better align its manufacturing and supply chain to its commercial activities, third-party costs incurred to support the transformation of certain general and administrative functions and the integration of its acquisition of Hill-Rom Holdings, Inc. (Hillrom). The company's results of discontinued operations in 2024 and 2023 included costs primarily related to inventory write-offs due to the exit of a product line and the decision to cease production of dialyzers at one of its |
2 |
The company’s results in 2024 and 2023 included integration-related items comprised of Hillrom acquisition and integration expenses. |
3 |
The company’s results in 2024 and 2023 included incremental costs to comply with the European Union’s medical device regulations for previously registered products, which primarily consisted of contractor costs and other direct third-party costs. The company considers the adoption of these regulations to be a significant one-time regulatory change and believes that the costs of initial compliance for previously registered products over the implementation period are not indicative of its core operating results. |
4 |
The company's results in 2024 included charges related to a revised estimate of warranty and remediation activities arising from a field corrective action on certain of our infusion pumps initially recorded in 2022. |
5 |
The company's results in 2024 included net charges related to Hurricane Helene. This amount consisted of a charge related to damaged inventory and fixed assets, partially offset by a benefit related to insurance recoveries expected as a result of those asset write-offs. |
6 |
The company’s results in 2024 included charges related to environmental reserves for remediation actions associated with historic operations at certain of our facilities. The company’s results in 2023 included costs, including associated legal fees related to matters involving alleged violations of the False Claims Act related to a now-discontinued legacy Hillrom sales line and alleged injury from environmental exposure. |
7 |
The company's results of discontinued operations in 2024 and 2023 included separation-related costs primarily related to external advisors supporting its activities to prepare for the pending sale of its Kidney Care segment. The company's results in 2023 also included separation-related costs related to the sale of its BioPharma Solutions (BPS) business. |
8 |
The company's results of discontinued operations in 2023 included long-lived asset impairment charges related to the Hemodialysis business within its Kidney Care segment. |
9 |
The company's results of discontinued operations in 2023 included a gain from the sale of the BPS business. |
10 |
The company's results of continuing operations in 2024 included tax items consisting of a valuation allowance recorded to reduce the carrying amount of a tax attributable carryforward in the |
For more information on the company's use of non-GAAP financial measures, please see the Non-GAAP Financial Measures section of this press release. |
BAXTER INTERNATIONAL INC. Consolidated Statements of Income (Loss) (unaudited) (in millions, except per share and percentage data)
|
|||||||||
|
Nine Months Ended
|
|
|
||||||
|
|
2024 |
|
|
|
2023 |
|
|
Change |
NET SALES |
$ |
7,883 |
|
|
$ |
7,634 |
|
|
|
COST OF SALES |
|
4,858 |
|
|
|
4,584 |
|
|
|
GROSS MARGIN |
|
3,025 |
|
|
|
3,050 |
|
|
(1)% |
% of Net Sales |
|
38.4 |
% |
|
|
40.0 |
% |
|
(1.6) pts |
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES |
|
2,206 |
|
|
|
2,270 |
|
|
(3)% |
% of Net Sales |
|
28.0 |
% |
|
|
29.7 |
% |
|
(1.7) pts |
RESEARCH AND DEVELOPMENT EXPENSES |
|
379 |
|
|
|
391 |
|
|
(3)% |
% of Net Sales |
|
4.8 |
% |
|
|
5.1 |
% |
|
(0.3) pts |
OTHER OPERATING INCOME, NET |
|
(9 |
) |
|
|
(14 |
) |
|
(36)% |
OPERATING INCOME |
|
449 |
|
|
|
403 |
|
|
|
% of Net Sales |
|
5.7 |
% |
|
|
5.3 |
% |
|
0.4 pts |
INTEREST EXPENSE, NET |
|
251 |
|
|
|
367 |
|
|
(32)% |
OTHER (INCOME) EXPENSE, NET |
|
(34 |
) |
|
|
15 |
|
|
NM |
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES |
|
232 |
|
|
|
21 |
|
|
NM |
INCOME TAX EXPENSE |
|
70 |
|
|
|
59 |
|
|
|
% of Income from Continuing Operations Before Income Taxes |
|
30.2 |
% |
|
|
281.0 |
% |
|
NM |
INCOME (LOSS) FROM CONTINUING OPERATIONS |
|
162 |
|
|
|
(38 |
) |
|
NM |
INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAX |
|
(290 |
) |
|
|
2,455 |
|
|
NM |
NET INCOME (LOSS) |
|
(128 |
) |
|
|
2,417 |
|
|
NM |
NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS INCLUDED IN CONTINUING OPERATIONS |
|
— |
|
|
|
— |
|
|
NM |
NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS INCLUDED IN DISCONTINUED OPERATIONS |
|
9 |
|
|
|
6 |
|
|
|
NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS |
|
9 |
|
|
|
6 |
|
|
|
NET LOSS ATTRIBUTABLE TO BAXTER STOCKHOLDERS |
$ |
(137 |
) |
|
$ |
2,411 |
|
|
NM |
INCOME (LOSS) FROM CONTINUING OPERATIONS PER COMMON SHARE |
|
|
|
|
|
||||
Basic |
$ |
0.32 |
|
|
$ |
(0.08 |
) |
|
NM |
Diluted |
$ |
0.32 |
|
|
$ |
(0.08 |
) |
|
NM |
INCOME (LOSS) FROM DISCONTINUED OPERATIONS PER COMMON SHARE |
|
|
|
|
|
||||
Basic |
$ |
(0.59 |
) |
|
$ |
4.84 |
|
|
NM |
Diluted |
$ |
(0.59 |
) |
|
$ |
4.84 |
|
|
NM |
NET INCOME (LOSS) PER COMMON SHARE |
|
|
|
|
|
||||
Basic |
$ |
(0.27 |
) |
|
$ |
4.76 |
|
|
NM |
Diluted |
$ |
(0.27 |
) |
|
$ |
4.76 |
|
|
NM |
WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING |
|
|
|
|
|
||||
Basic |
|
509 |
|
|
|
506 |
|
|
|
Diluted |
|
511 |
|
|
|
506 |
|
|
|
ADJUSTED OPERATING INCOME (excluding special items)¹ |
$ |
1,055 |
|
|
$ |
1,051 |
|
|
|
ADJUSTED INCOME FROM CONTINUING OPERATIONS (excluding special items)¹ |
$ |
669 |
|
|
$ |
533 |
|
|
|
ADJUSTED INCOME FROM DISCONTINUED OPERATIONS (excluding special items)1 |
$ |
427 |
|
|
$ |
520 |
|
|
(18)% |
ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER STOCKHOLDERS (excluding special items)¹ |
$ |
1,087 |
|
|
$ |
1,047 |
|
|
|
ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS (excluding special items)1 |
$ |
1.31 |
|
|
$ |
1.05 |
|
|
|
ADJUSTED DILUTED EPS FROM DISCONTINUED OPERATIONS (excluding special items)1 |
$ |
0.82 |
|
|
$ |
1.02 |
|
|
(20)% |
ADJUSTED DILUTED EPS (excluding special items)¹ |
$ |
2.13 |
|
|
$ |
2.07 |
|
|
|
1 |
Refer to page 13 for a description of the adjustments and a reconciliation to |
NM - Not Meaningful |
BAXTER INTERNATIONAL INC.
Description of Adjustments and Reconciliation of (unaudited, in millions)
The company’s
|
|||||||||||||||||||||||||||||||||||
|
Gross Margin |
Selling, General and Administrative Expenses |
Operating Income |
Income From Continuing Operations Before Income Taxes |
Income Tax Expense |
Income (Loss) From Continuing Operations |
Income (Loss) From Discontinued Operations, Net of Tax |
Net Income (Loss) |
Net Income (Loss) Attributable to Baxter Stockholders |
Diluted Earnings Per Share From Continuing Operations |
Diluted Earnings Per Share from Discontinued Operations |
Diluted Earnings Per Share |
|||||||||||||||||||||||
Reported |
$ |
3,025 |
|
$ |
2,206 |
|
$ |
449 |
|
$ |
232 |
|
$ |
70 |
|
$ |
162 |
|
$ |
(290 |
) |
$ |
(128 |
) |
$ |
(137 |
) |
$ |
0.32 |
$ |
(0.59 |
) |
$ |
(0.27 |
) |
Reported percent of net sales (or effective tax rate for income tax expense) |
|
38.4 |
% |
|
28.0 |
% |
|
5.7 |
% |
|
2.9 |
% |
|
30.2 |
% |
|
2.1 |
% |
|
(3.7 |
)% |
|
(1.6 |
)% |
|
(1.7 |
)% |
|
|
|
|||||
Intangible asset amortization |
|
316 |
|
|
(155 |
) |
|
471 |
|
|
471 |
|
|
111 |
|
|
360 |
|
|
19 |
|
|
379 |
|
|
379 |
|
|
0.70 |
|
0.04 |
|
|
0.74 |
|
Business optimization items1 |
|
8 |
|
|
(41 |
) |
|
49 |
|
|
49 |
|
|
14 |
|
|
35 |
|
|
53 |
|
|
88 |
|
|
88 |
|
|
0.07 |
|
0.10 |
|
|
0.17 |
|
Acquisition and integration items2 |
|
1 |
|
|
(15 |
) |
|
16 |
|
|
16 |
|
|
3 |
|
|
13 |
|
|
— |
|
|
13 |
|
|
13 |
|
|
0.03 |
|
0.00 |
|
|
0.03 |
|
European medical devices regulation3 |
|
25 |
|
|
— |
|
|
25 |
|
|
25 |
|
|
6 |
|
|
19 |
|
|
3 |
|
|
22 |
|
|
22 |
|
|
0.04 |
|
0.00 |
|
|
0.04 |
|
Product-related reserves4 |
|
3 |
|
|
— |
|
|
3 |
|
|
3 |
|
|
— |
|
|
3 |
|
|
— |
|
|
3 |
|
|
3 |
|
|
0.01 |
|
0.00 |
|
|
0.01 |
|
Hurricane Helene costs5 |
|
25 |
|
|
— |
|
|
25 |
|
|
25 |
|
|
6 |
|
|
19 |
|
|
— |
|
|
19 |
|
|
19 |
|
|
0.04 |
|
0.00 |
|
|
0.04 |
|
Legal matters6 |
|
— |
|
|
(17 |
) |
|
17 |
|
|
17 |
|
|
4 |
|
|
13 |
|
|
— |
|
|
13 |
|
|
13 |
|
|
0.03 |
|
0.00 |
|
|
0.03 |
|
Separation-related costs8 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
193 |
|
|
193 |
|
|
193 |
|
|
0.00 |
|
0.38 |
|
|
0.38 |
|
Goodwill impairment9 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
430 |
|
|
430 |
|
|
430 |
|
|
0.00 |
|
0.84 |
|
|
0.84 |
|
Tax Matters12 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(45 |
) |
|
45 |
|
|
19 |
|
|
64 |
|
|
64 |
|
|
0.09 |
|
0.04 |
|
|
0.13 |
|
Adjusted |
$ |
3,403 |
|
$ |
1,978 |
|
$ |
1,055 |
|
$ |
838 |
|
$ |
169 |
|
$ |
669 |
|
$ |
427 |
|
$ |
1,096 |
|
$ |
1,087 |
|
$ |
1.31 |
$ |
0.82 |
|
$ |
2.13 |
|
Adjusted percent of net sales (or effective tax rate for income tax expense) |
|
43.2 |
% |
|
25.1 |
% |
|
13.4 |
% |
|
10.6 |
% |
|
20.2 |
% |
|
8.5 |
% |
|
5.4 |
% |
|
13.9 |
% |
|
13.8 |
% |
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
|
|
|
|
Reported |
Adjusted |
|
|
|
|
|
|
|
|||||||||||||||||||||||
Income (loss) from discontinued operations, net of tax |
$ |
(290 |
) |
$ |
427 |
|
|
|
|
|
|
|
|
||||||||||||||||||||||
Less: Net income attributable to noncontrolling interests included in discontinued operations |
|
9 |
|
|
9 |
|
|
|
|
|
|
|
|
||||||||||||||||||||||
Income (loss) from discontinued operations, net of tax attributable to Baxter stockholders |
$ |
(299 |
) |
$ |
418 |
|
|
|
|
|
|
|
|
||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
|
|
|
|
Reported |
Adjusted |
|
|
|
|
|
|
|
|||||||||||||||||||||||
Net income (loss) |
|
|
|
|
|
|
|
$ |
(128 |
) |
$ |
1,096 |
|
|
|
|
|
|
|
|
|||||||||||||||
Less: Net income attributable to noncontrolling interests |
|
|
9 |
|
|
9 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Net income (loss) attributable to Baxter stockholders |
|
|
|
$ |
(137 |
) |
$ |
1,087 |
|
|
|
|
|
|
|
|
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
The company’s
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Gross Margin |
Selling, General and Administrative Expenses |
Research and Development Expenses |
Other Operating Income, Net |
Operating Income |
Other Expense, Net |
Income From Continuing Operations Before Income Taxes |
Income Tax Expense |
Income (Loss) From Continuing Operations |
Income (Loss) From Discontinued Operations, Net of Tax |
Net Income (Loss) |
Net Income (Loss) Attributable to Baxter Stockholders |
Diluted Earnings Per Share From Continuing Operations |
Diluted Earnings Per Share From Discontinued Operations |
Diluted Earnings Per Share |
||||||||||||||||||||||||||||||
Reported |
$ |
3,050 |
|
$ |
2,270 |
|
$ |
391 |
|
$ |
(14 |
) |
$ |
403 |
|
$ |
15 |
|
$ |
21 |
|
$ |
59 |
|
$ |
(38 |
) |
$ |
2,455 |
|
$ |
2,417 |
|
$ |
2,411 |
|
$ |
(0.08 |
) |
$ |
4.84 |
$ |
4.76 |
||
Reported percent of net sales (or effective tax rate for income tax expense) |
|
40.0 |
% |
|
29.7 |
% |
|
5.1 |
% |
|
(0.2 |
)% |
|
5.3 |
% |
|
0.2 |
% |
|
0.3 |
% |
|
281.0 |
% |
|
(0.5 |
)% |
|
32.2 |
% |
|
31.7 |
% |
|
31.6 |
% |
|
|
|
||||||
Intangible asset amortization |
|
279 |
|
|
(155 |
) |
|
— |
|
|
— |
|
|
434 |
|
|
— |
|
|
434 |
|
|
99 |
|
|
335 |
|
|
40 |
|
|
375 |
|
|
375 |
|
|
0.66 |
|
|
0.08 |
|
|
0.74 |
|
Business optimization items1 |
|
23 |
|
|
(134 |
) |
|
(10 |
) |
|
— |
|
|
167 |
|
|
— |
|
|
167 |
|
|
38 |
|
|
129 |
|
|
288 |
|
|
417 |
|
|
417 |
|
|
0.25 |
|
|
0.57 |
|
|
0.82 |
|
Acquisition and integration items2 |
|
1 |
|
|
(15 |
) |
|
— |
|
|
14 |
|
|
2 |
|
|
— |
|
|
2 |
|
|
1 |
|
|
1 |
|
|
— |
|
|
1 |
|
|
1 |
|
|
0.00 |
|
|
0.00 |
|
|
0.00 |
|
European medical devices regulation3 |
|
32 |
|
|
— |
|
|
— |
|
|
— |
|
|
32 |
|
|
— |
|
|
32 |
|
|
10 |
|
|
22 |
|
|
5 |
|
|
27 |
|
|
27 |
|
|
0.04 |
|
|
0.01 |
|
|
0.05 |
|
Legal matters6 |
|
— |
|
|
(13 |
) |
|
— |
|
|
— |
|
|
13 |
|
|
— |
|
|
13 |
|
|
3 |
|
|
10 |
|
|
— |
|
|
10 |
|
|
10 |
|
|
0.02 |
|
|
0.00 |
|
|
0.02 |
|
Investment impairments7 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(10 |
) |
|
10 |
|
|
3 |
|
|
7 |
|
|
8 |
|
|
15 |
|
|
15 |
|
|
0.01 |
|
|
0.02 |
|
|
0.03 |
|
Separation-related costs8 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
142 |
|
|
142 |
|
|
142 |
|
|
0.00 |
|
|
0.28 |
|
|
0.28 |
|
Long-lived asset impairments10 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
205 |
|
|
205 |
|
|
205 |
|
|
0.00 |
|
|
0.40 |
|
|
0.40 |
|
Gain on BPS Sale11 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(2,603 |
) |
|
(2,603 |
) |
|
(2,603 |
) |
|
0.00 |
|
|
(5.13 |
) |
|
(5.13 |
) |
Tax matters12 |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(67 |
) |
|
67 |
|
|
(20 | ) |
|
47 |
|
|
47 |
|
|
0.13 |
|
|
0.04 |
|
|
0.09 |
|
Adjusted |
$ |
3,385 |
|
$ |
1,953 |
|
$ |
381 |
|
$ |
— |
|
$ |
1,051 |
|
$ |
5 |
|
$ |
679 |
|
$ |
146 |
|
$ |
533 |
|
$ |
520 |
|
$ |
1,053 |
|
$ |
1,047 |
|
$ |
1.05 |
|
$ |
1.02 |
|
$ |
2.07 |
|
Adjusted percent of net sales (or effective tax rate for income tax expense) |
|
44.3 |
% |
|
25.6 |
% |
|
5.0 |
% |
|
0.0 |
% |
|
13.8 |
% |
|
0.1 |
% |
|
8.9 |
% |
|
21.5 |
% |
|
7.0 |
% |
|
6.8 |
% |
|
13.8 |
% |
|
13.7 |
% |
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
Reported |
Adjusted |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||
Income (loss) from discontinued operations, net of tax |
|
|
|
$ |
2,455 |
|
$ |
520 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||
Less: Net income attributable to noncontrolling interests included in discontinued operations |
|
|
6 |
|
|
6 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||
Income (loss) from discontinued operations, net of tax attributable to Baxter stockholders |
|
$ |
2,449 |
|
$ |
514 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
Reported |
Adjusted |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||
Net income (loss) |
|
$ |
2,417 |
|
$ |
1,053 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||
Less: Net income attributable to noncontrolling interests |
|
|
6 |
|
|
6 |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||
Net income (loss) attributable to Baxter stockholders |
$ |
2,411 |
|
$ |
1,047 |
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||
Weighted-average diluted shares as reported |
|
506 |
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Effect of dilutive securities that were anti-dilutive to dilutive EPS as reported |
|
1 |
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Weighted-average diluted shares as adjusted |
|
507 |
|
|
|
|
|
|
|
|
|
1. |
The company’s results in 2024 and 2023 included costs related to programs to optimize its organization and cost structure. The company's results of continuing operations in 2024 and 2023 included costs primarily related to our implementation of a new operating model intended to simplify and streamline our operations and better align our manufacturing and supply chain to our commercial activities, third-party costs incurred to support the transformation of certain general and administrative functions and the integration of its acquisition of Hill-Rom Holdings, Inc. (Hillrom). The company's results of discontinued operations in 2024 and 2023, included costs primarily related to a program to centralize certain of its research and development activities into a new location, property plant and equipment impairments in connection with the transfer of a manufacturing production line as part of its initiatives to optimize its global manufacturing and supply chain organization, the decision to cease production of dialyzers at one of its |
2. |
The company’s results in 2024 and 2023 included integration-related items comprised of Hillrom acquisition and integration expenses. In 2023 those costs are offset by net gains from changes in the fair value of contingent consideration liabilities. |
3. |
The company’s results in 2024 and 2023 included incremental costs to comply with the European Union’s medical device regulations for previously registered products, which primarily consist of contractor costs and other direct third-party costs. The company considers the adoption of these regulations to be a significant one-time regulatory change and believes that the costs of initial compliance for previously registered products over the implementation period are not indicative of its core operating results. |
4. |
The company's results in 2024 included charges related to a revised estimate of warranty and remediation activities arising from a field corrective action on certain of our infusion pumps initially recorded in 2022. |
5. |
The company's results in 2024 included net charges related to Hurricane Helene. This amount consisted of a charge related to damaged inventory and fixed assets, partially offset by a benefit related to insurance recoveries expected as a result of those asset write-offs. |
6. |
The company’s results in 2024 included charges related to environmental reserves for remediation actions associated with historic operations at certain of our facilities. The company’s results in 2023 included costs, including associated legal fees related to matters involving alleged violations of the False Claims Act related to a now-discontinued legacy Hillrom sales line and alleged injury from environmental exposure. |
7. |
The company's results of continuing operations in 2023 included losses from non-marketable investments in several early stage companies, consisting of noncash impairment write-downs, partially offset by a |
8. |
The company's results of discontinued operations in 2024 and 2023 included separation-related costs primarily related to external advisors supporting its activities to prepare for the pending sale of its Kidney Care segment. The company's results in 2023 also included separation-related costs related to the sale of its BioPharma Solutions (BPS) business. |
9. |
The company's results of discontinued operations in 2024 included a charge related to a goodwill impairment of the company's Chronic Therapies reporting unit within its Kidney Care segment. |
10. |
The company's results of discontinued operations in 2023 included long-lived asset impairment charges related to the Hemodialysis business within its Kidney Care segment. |
11. |
The company's results of discontinued operations in 2023 included a gain from the sale of its BPS business. |
12. |
The company's results in 2024 included income tax items consisting of a |
For more information on the company's use of non-GAAP financial measures, please see the Non-GAAP Financial Measures section of this press release. |
BAXTER INTERNATIONAL INC. Sales by Operating Segment (unaudited) ($ in millions)
|
|||||||||||||||||||||
The Medical Products and Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding. Other sales not allocated to a segment primarily include sales of products and services provided directly through certain of our manufacturing facilities.
|
|||||||||||||||||||||
|
Three Months Ended
|
% Growth @ Actual Rates |
% Growth @ Constant Rates |
|
Nine Months Ended
|
% Growth @ Actual Rates |
% Growth @ Constant Rates |
||||||||||||||
|
|
2024 |
|
|
2023 |
|
|
|
2024 |
|
|
2023 |
|
||||||||
Infusion Therapies and Technologies |
$ |
1,070 |
$ |
1,003 |
7 |
% |
7 |
% |
|
$ |
3,081 |
$ |
2,918 |
6 |
% |
6 |
% |
||||
Advanced Surgery |
|
272 |
|
|
255 |
|
7 |
% |
7 |
% |
|
|
812 |
|
|
773 |
|
5 |
% |
6 |
% |
Medical Products and Therapies |
|
1,342 |
|
|
1,258 |
|
7 |
% |
7 |
% |
|
|
3,893 |
|
|
3,691 |
|
5 |
% |
6 |
% |
Care and Connectivity Solutions |
|
456 |
|
|
443 |
|
3 |
% |
3 |
% |
|
|
1,310 |
|
|
1,307 |
|
0 |
% |
0 |
% |
Front Line Care |
|
296 |
|
|
301 |
|
(2 |
)% |
(2 |
)% |
|
|
857 |
|
|
911 |
|
(6 |
)% |
(6 |
)% |
Healthcare Systems and Technologies |
|
752 |
|
|
744 |
|
1 |
% |
1 |
% |
|
|
2,167 |
|
|
2,218 |
|
(2 |
)% |
(3 |
)% |
Injectables and Anesthesia |
|
321 |
|
|
351 |
|
(9 |
)% |
(9 |
)% |
|
|
990 |
|
|
987 |
|
0 |
% |
1 |
% |
Drug Compounding |
|
267 |
|
|
229 |
|
17 |
% |
14 |
% |
|
|
778 |
|
|
665 |
|
17 |
% |
17 |
% |
Pharmaceuticals |
|
588 |
|
|
580 |
|
1 |
% |
1 |
% |
|
|
1,768 |
|
|
1,652 |
|
7 |
% |
7 |
% |
Other |
|
17 |
|
|
17 |
|
0 |
% |
12 |
% |
|
|
55 |
|
|
73 |
|
(25 |
)% |
(23 |
)% |
Total - Continuing Operations |
$ |
2,699 |
|
$ |
2,599 |
|
4 |
% |
4 |
% |
|
$ |
7,883 |
|
$ |
7,634 |
|
3 |
% |
3 |
% |
Constant currency growth is a non-GAAP measure. For more information on the company’s use of non-GAAP financial measures, please see the Non-GAAP Financial Measures section of this press release. |
BAXTER INTERNATIONAL INC. Segment Operating Income (unaudited) ($ in millions)
|
|||||||||||||
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||
|
|
2024 |
|
|
2023 |
|
|
|
2024 |
|
|
2023 |
|
Medical Products and Therapies |
$ |
268 |
|
$ |
245 |
|
|
$ |
733 |
|
$ |
706 |
|
% of Segment Net Sales |
|
20.0 |
% |
|
19.5 |
% |
|
|
18.8 |
% |
|
19.1 |
% |
Healthcare Systems and Technologies |
|
136 |
|
|
115 |
|
|
|
323 |
|
|
327 |
|
% of Segment Net Sales |
|
18.1 |
% |
|
15.5 |
% |
|
|
14.9 |
% |
|
14.7 |
% |
Pharmaceuticals |
|
58 |
|
|
108 |
|
|
|
211 |
|
|
284 |
|
% of Segment Net Sales |
|
9.9 |
% |
|
18.6 |
% |
|
|
11.9 |
% |
|
17.2 |
% |
Other |
|
2 |
|
|
6 |
|
|
|
15 |
|
|
19 |
|
Total |
|
464 |
|
|
474 |
|
|
|
1,282 |
|
|
1,336 |
|
Unallocated corporate costs |
|
(73 |
) |
|
(73 |
) |
|
|
(227 |
) |
|
(285 |
) |
Intangible asset amortization expense |
|
(159 |
) |
|
(147 |
) |
|
|
(471 |
) |
|
(434 |
) |
Legal matters |
|
(17 |
) |
|
(13 |
) |
|
|
(17 |
) |
|
(13 |
) |
Business optimization items |
|
(18 |
) |
|
(48 |
) |
|
|
(49 |
) |
|
(167 |
) |
Acquisition and integration items |
|
(5 |
) |
|
(2 |
) |
|
|
(16 |
) |
|
(2 |
) |
European Medical Devices Regulation |
|
(9 |
) |
|
(12 |
) |
|
|
(25 |
) |
|
(32 |
) |
Product-related items |
|
(3 |
) |
|
— |
|
|
|
(3 |
) |
|
— |
|
Hurricane Helene costs |
|
(25 |
) |
|
— |
|
|
|
(25 |
) |
|
— |
|
Total operating income (loss) |
|
155 |
|
|
179 |
|
|
|
449 |
|
|
403 |
|
Interest expense, net |
|
87 |
|
|
127 |
|
|
|
251 |
|
|
367 |
|
Other (income) expense, net |
|
(1 |
) |
|
(12 |
) |
|
|
(34 |
) |
|
15 |
|
Loss from continuing operations before income taxes |
$ |
69 |
|
$ |
64 |
|
|
$ |
232 |
|
$ |
21 |
|
BAXTER INTERNATIONAL INC.
Operating Segment Sales by (unaudited) ($ in millions)
|
||||||||||||||||||||||||||
|
Three Months Ended September 30, |
|
|
|
|
|||||||||||||||||||||
|
2024 |
|
2023 |
|
% Growth |
|||||||||||||||||||||
|
|
International |
Total |
|
|
International |
Total |
|
|
International |
Total |
|||||||||||||||
Infusion Therapies and Technologies |
$ |
613 |
$ |
457 |
$ |
1,070 |
|
$ |
570 |
$ |
433 |
$ |
1,003 |
|
8 |
% |
6 |
% |
7 |
% |
||||||
Advanced Surgery |
|
149 |
|
|
123 |
|
|
272 |
|
|
|
139 |
|
|
116 |
|
|
255 |
|
|
7 |
% |
6 |
% |
7 |
% |
Medical Products and Therapies |
|
762 |
|
|
580 |
|
|
1,342 |
|
|
|
709 |
|
|
549 |
|
|
1,258 |
|
|
7 |
% |
6 |
% |
7 |
% |
Care and Connectivity Solutions |
|
335 |
|
|
121 |
|
|
456 |
|
|
|
317 |
|
|
126 |
|
|
443 |
|
|
6 |
% |
(4 |
)% |
3 |
% |
Front Line Care |
|
222 |
|
|
74 |
|
|
296 |
|
|
|
234 |
|
|
67 |
|
|
301 |
|
|
(5 |
)% |
10 |
% |
(2 |
)% |
Healthcare Systems and Technologies |
|
557 |
|
|
195 |
|
|
752 |
|
|
|
551 |
|
|
193 |
|
|
744 |
|
|
1 |
% |
1 |
% |
1 |
% |
Injectables and Anesthesia |
|
178 |
|
|
143 |
|
|
321 |
|
|
|
195 |
|
|
156 |
|
|
351 |
|
|
(9 |
)% |
(8 |
)% |
(9 |
)% |
Drug Compounding |
|
— |
|
|
267 |
|
|
267 |
|
|
|
— |
|
|
229 |
|
|
229 |
|
|
0 |
% |
17 |
% |
17 |
% |
Pharmaceuticals |
|
178 |
|
|
410 |
|
|
588 |
|
|
|
195 |
|
|
385 |
|
|
580 |
|
|
(9 |
)% |
6 |
% |
1 |
% |
Other |
|
3 |
|
|
14 |
|
|
17 |
|
|
|
12 |
|
|
5 |
|
|
17 |
|
|
(75 |
)% |
180 |
% |
0 |
% |
Total - Continuing Operations |
$ |
1,500 |
|
$ |
1,199 |
|
$ |
2,699 |
|
|
$ |
1,467 |
|
$ |
1,132 |
|
$ |
2,599 |
|
|
2 |
% |
6 |
% |
4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
BAXTER INTERNATIONAL INC.
Operating Segment Sales by (unaudited) ($ in millions)
|
||||||||||||||||||||||||||
|
Nine Months Ended September 30, |
|
|
|
|
|||||||||||||||||||||
|
2024 |
|
2023 |
|
% Growth |
|||||||||||||||||||||
|
|
International |
Total |
|
|
International |
Total |
|
|
International |
Total |
|||||||||||||||
Infusion Therapies and Technologies |
$ |
1,718 |
$ |
1,363 |
$ |
3,081 |
|
$ |
1,654 |
$ |
1,264 |
$ |
2,918 |
|
4 |
% |
8 |
% |
6 |
% |
||||||
Advanced Surgery |
|
446 |
|
|
366 |
|
|
812 |
|
|
|
433 |
|
|
340 |
|
|
773 |
|
|
3 |
% |
8 |
% |
5 |
% |
Medical Products and Therapies |
|
2,164 |
|
|
1,729 |
|
|
3,893 |
|
|
|
2,087 |
|
|
1,604 |
|
|
3,691 |
|
|
4 |
% |
8 |
% |
5 |
% |
Care and Connectivity Solutions |
|
945 |
|
|
365 |
|
|
1,310 |
|
|
|
926 |
|
|
381 |
|
|
1,307 |
|
|
2 |
% |
(4 |
)% |
0 |
% |
Front Line Care |
|
635 |
|
|
222 |
|
|
857 |
|
|
|
681 |
|
|
230 |
|
|
911 |
|
|
(7 |
)% |
(3 |
)% |
(6 |
)% |
Healthcare Systems and Technologies |
|
1,580 |
|
|
587 |
|
|
2,167 |
|
|
|
1,607 |
|
|
611 |
|
|
2,218 |
|
|
(2 |
)% |
(4 |
)% |
(2 |
)% |
Injectables and Anesthesia |
|
566 |
|
|
424 |
|
|
990 |
|
|
|
550 |
|
|
437 |
|
|
987 |
|
|
3 |
% |
(3 |
)% |
0 |
% |
Drug Compounding |
|
— |
|
|
778 |
|
|
778 |
|
|
|
— |
|
|
665 |
|
|
665 |
|
|
0 |
% |
17 |
% |
17 |
% |
Pharmaceuticals |
|
566 |
|
|
1,202 |
|
|
1,768 |
|
|
|
550 |
|
|
1,102 |
|
|
1,652 |
|
|
3 |
% |
9 |
% |
7 |
% |
Other |
|
30 |
|
|
25 |
|
|
55 |
|
|
|
56 |
|
|
17 |
|
|
73 |
|
|
(46 |
)% |
47 |
% |
(25 |
)% |
Total - Continuing Operations |
$ |
4,340 |
|
$ |
3,543 |
|
$ |
7,883 |
|
|
$ |
4,300 |
|
$ |
3,334 |
|
$ |
7,634 |
|
|
1 |
% |
6 |
% |
3 |
% |
BAXTER INTERNATIONAL INC. Reconciliation of Non-GAAP Financial Measure Operating Cash Flow to Free Cash Flow (unaudited) ($ in millions)
|
|||||||
|
Nine Months Ended September 30, |
||||||
|
|
2024 |
|
|
|
2023 |
|
Cash flows from operations – continuing operations |
$ |
376 |
|
|
$ |
792 |
|
Cash flows from investing activities - continuing operations |
|
(281 |
) |
|
|
(325 |
) |
Cash flows from financing activities - continuing operations |
|
(1,222 |
) |
|
|
(554 |
) |
|
|
|
|
||||
Cash flows from operations - continuing operations |
$ |
376 |
|
|
$ |
792 |
|
Capital expenditures - continuing operations |
|
(314 |
) |
|
|
(340 |
) |
Free cash flow - continuing operations |
$ |
62 |
|
|
$ |
452 |
|
|
Nine Months Ended September 30, |
||||||
|
|
2024 |
|
|
|
2023 |
|
Cash flows from operations – discontinued operations |
$ |
155 |
|
|
$ |
403 |
|
Cash flows from investing activities - discontinued operations |
|
(140 |
) |
|
|
3,768 |
|
|
|
|
|
||||
Cash flows from operations - discontinued operations |
$ |
155 |
|
|
$ |
403 |
|
Capital expenditures - discontinued operations |
|
(138 |
) |
|
|
(189 |
) |
Free cash flow - discontinued operations |
$ |
17 |
|
|
$ |
214 |
|
|
Nine Months Ended September 30, |
||||||
|
|
2024 |
|
|
|
2023 |
|
Cash flows from operations – Total Baxter |
$ |
531 |
|
|
$ |
1,195 |
|
Cash flows from investing activities - Total Baxter |
|
(421 |
) |
|
|
3,443 |
|
Cash flows from financing activities - Total Baxter |
|
(1,222 |
) |
|
|
(554 |
) |
|
|
|
|
||||
Cash flows from operations - Total Baxter |
$ |
531 |
|
|
$ |
1,195 |
|
Capital expenditures - Total Baxter |
|
(452 |
) |
|
|
(529 |
) |
Free cash flow - Total Baxter |
$ |
79 |
|
|
$ |
666 |
|
Free cash flow is a non-GAAP measure. For more information on the company’s use of non-GAAP financial measures, please see the Non-GAAP Financial Measures section of this press release. |
BAXTER INTERNATIONAL INC. Reconciliation of Non-GAAP Financial Measure Change in Net Sales Growth As Reported to Constant Currency Sales Growth From the Three Months Ended September 30, 2023 to the Three Months Ended September 30, 2024 (unaudited)
|
||||||
|
Net Sales Growth As Reported |
FX |
Constant Currency Sales Growth* |
|||
Infusion Therapies and Technologies |
7 |
% |
0 |
% |
7 |
% |
Advanced Surgery |
7 |
% |
0 |
% |
7 |
% |
Medical Products and Therapies |
7 |
% |
0 |
% |
7 |
% |
Care and Connectivity Solutions |
3 |
% |
0 |
% |
3 |
% |
Front Line Care |
(2 |
)% |
0 |
% |
(2 |
)% |
Healthcare Systems and Technologies |
1 |
% |
0 |
% |
1 |
% |
Injectables and Anesthesia |
(9 |
)% |
0 |
% |
(9 |
)% |
Drug Compounding |
17 |
% |
(3 |
)% |
14 |
% |
Pharmaceuticals |
1 |
% |
0 |
% |
1 |
% |
Other |
0 |
% |
12 |
% |
12 |
% |
Total - Continuing Operations |
4 |
% |
0 |
% |
4 |
% |
Discontinued Operations - Kidney Care |
4 |
% |
1 |
% |
5 |
% |
Total - Continuing Operations and Discontinued Operations - Kidney Care |
4 |
% |
0 |
% |
4 |
% |
Discontinued Operations - BioPharma Solutions (BPS)1 |
NM |
|
NM |
|
NM |
|
Total Baxter |
(1 |
)% |
0 |
% |
(1 |
)% |
1 |
The company's BPS business was sold in the third quarter of 2023. |
*Totals may not add across due to rounding |
|
Constant currency sales growth is a non-GAAP measure. For more information on the company’s use of non-GAAP financial measures, please see the Non-GAAP Financial Measures section of this press release. |
BAXTER INTERNATIONAL INC. Reconciliation of Non-GAAP Financial Measure Change in Net Sales Growth As Reported to Constant Currency Sales Growth From The Nine Months Ended September 30, 2023 to The Nine Months Ended September 30, 2024 (unaudited)
|
||||||
|
Net Sales Growth As Reported |
FX |
Constant Currency Sales Growth* |
|||
Infusion Therapies and Technologies |
6 |
% |
0 |
% |
6 |
% |
Advanced Surgery |
5 |
% |
1 |
% |
6 |
% |
Medical Products and Therapies |
5 |
% |
1 |
% |
6 |
% |
Care and Connectivity Solutions |
0 |
% |
0 |
% |
0 |
% |
Front Line Care |
(6 |
)% |
0 |
% |
(6 |
)% |
Healthcare Systems and Technologies |
(2 |
)% |
(1 |
)% |
(3 |
)% |
Injectables and Anesthesia |
0 |
% |
1 |
% |
1 |
% |
Drug Compounding |
17 |
% |
0 |
% |
17 |
% |
Pharmaceuticals |
7 |
% |
0 |
% |
7 |
% |
Other |
(25 |
)% |
2 |
% |
(23 |
)% |
Total - Continuing Operations |
3 |
% |
0 |
% |
3 |
% |
Discontinued Operations - Kidney Care |
2 |
% |
2 |
% |
4 |
% |
Total - Continuing Operations and Discontinued Operations - Kidney Care |
3 |
% |
1 |
% |
4 |
% |
*Totals may not add across due to rounding |
Constant currency sales growth is a non-GAAP measure. For more information on the company’s use of non-GAAP financial measures, please see the Non-GAAP Financial Measures section of this press release. |
BAXTER INTERNATIONAL INC. Reconciliation of Non-GAAP Financial Measures Projected Fourth Quarter and Full Year 2024 U.S. GAAP Sales Growth to Projected Constant Currency Sales Growth and Projected Fourth Quarter and Full Year 2024 Adjusted Earnings Per Share (unaudited)
|
||
Sales Growth Guidance |
Q4 2024* |
FY 2024* |
Sales growth - |
Decline Low
|
|
Foreign Exchange |
<50 bps |
~50 bps |
Sales growth - Constant currency |
Decline Low
|
~ |
Adjusted Earnings Per Share Guidance |
Q4 2024 |
FY 2024 |
Adjusted diluted EPS |
|
|
Reconciliation of Non-GAAP Financial Measures Projected Annual Operational Sales Growth and Projected Full Year 2025 Adjusted Operating Margin (unaudited)
|
|
Operational Sales Growth Guidance |
Annually |
Operational sales growth |
|
Adjusted Operating Margin Guidance |
FY 2025 |
Adjusted operating margin |
~ |
*Totals may not foot due to rounding |
Baxter calculates forward-looking non-GAAP financial measures based on forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking annual operational sales guidance represents the company's targeted future sales growth excluding sales to Vantive under the related manufacturing supply agreement and assuming foreign currency exchange rates remain constant in future periods. Additionally, forward-looking full year 2025 adjusted operating margin guidance and forward-looking adjusted diluted EPS guidance excludes potential charges or gains that would be reflected as non-GAAP adjustments to earnings. Baxter provides forward-looking annual operational sales growth guidance, forward-looking full year 2025 adjusted operating margin guidance and forward-looking adjusted diluted EPS guidance because it believes that these measures provide useful information for the reasons noted in the accompanying release. Baxter has not provided reconciliations of forward-looking annual operational sales growth guidance to forward-looking GAAP reported sales growth guidance, forward-looking full year 2025 adjusted operating margin guidance to forward-looking GAAP operating margin guidance and forward-looking adjusted EPS guidance to forward-looking GAAP EPS guidance for the fourth quarter and full year of 2024 because the company is unable to predict with reasonable certainty the impact of legal proceedings, future business optimization actions, separation-related costs, integration-related costs, asset impairments, unusual gains and losses, and changes in foreign currency exchange rates, and the related amounts are unavailable without unreasonable efforts (as specified in the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K). In addition, Baxter believes that such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106549719/en/
Media Contact
Andrea Johnson, (224) 948-5353
media@baxter.com
Investor Contact
Clare Trachtman, (224) 948-3020
Source: Baxter International Inc.
FAQ
What was Baxter's (BAX) Q3 2024 revenue?
How much will Hurricane Helene impact Baxter's (BAX) Q4 2024 sales?
What is Baxter's (BAX) full-year 2024 guidance?